Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 3
2008 1
2010 1
2011 1
2012 1
2015 1
2017 1
2019 3
2020 5
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Surveillance of tuberculosis.
Schwoebel V. Schwoebel V. Indian J Tuberc. 2020 Dec;67(4S):S33-S42. doi: 10.1016/j.ijtb.2020.11.006. Epub 2020 Nov 15. Indian J Tuberc. 2020. PMID: 33308670 Review.
Multidrug-resistant tuberculosis.
Chiang CY, Van Deun A, Trébucq A, Piubello A, Schwoebel V, Rieder HL. Chiang CY, et al. Among authors: schwoebel v. Lancet. 2019 Jul 27;394(10195):299. doi: 10.1016/S0140-6736(19)30046-7. Lancet. 2019. PMID: 31354138 No abstract available.
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
Van Deun A, Decroo T, Tahseen S, Trébucq A, Schwoebel V, Ortuno-Gutierrez N, de Jong BC, Rieder HL, Piubello A, Chiang CY. Van Deun A, et al. Among authors: schwoebel v. Int J Antimicrob Agents. 2020 Jan;55(1):105822. doi: 10.1016/j.ijantimicag.2019.10.003. Epub 2019 Oct 15. Int J Antimicrob Agents. 2020. PMID: 31626907
The looming threat of bedaquiline resistance in tuberculosis.
Chiang CY, Trébucq A, Piubello A, Rieder HL, Schwoebel V, Van Deun A. Chiang CY, et al. Among authors: schwoebel v. Eur Respir J. 2020 Jun 4;55(6):2000718. doi: 10.1183/13993003.00718-2020. Print 2020 Jun. Eur Respir J. 2020. PMID: 32499309 Free article. No abstract available.
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis.
Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, Brode S, Campbell JR, Casas EC, Conradie F, Dravniece G, du Cros P, Falzon D, Jaramillo E, Kuaban C, Lan Z, Lange C, Li PZ, Makhmudova M, Maug AKJ, Menzies D, Migliori GB, Miller A, Myrzaliev B, Ndjeka N, Noeske J, Parpieva N, Piubello A, Schwoebel V, Sikhondze W, Singla R, Souleymane MB, Trébucq A, Van Deun A, Viney K, Weyer K, Zhang BJ, Ahmad Khan F. Abidi S, et al. Among authors: schwoebel v. Eur Respir J. 2020 Mar 20;55(3):1901467. doi: 10.1183/13993003.01467-2019. Print 2020 Mar. Eur Respir J. 2020. PMID: 31862767 Free article.
High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
Souleymane MB, Piubello A, Lawan IM, Hassane-Harouna S, Assao-Neino MM, Soumana A, Hamidou-Harouna Z, Gagara-Issoufou A, Ortuño-Gutiérrez N, Roggi A, Schwoebel V, Mamadou S, Lynen L, De Jong B, Van Deun A, Decroo T. Souleymane MB, et al. Among authors: schwoebel v. Eur Respir J. 2021 Jan 21;57(1):2002250. doi: 10.1183/13993003.02250-2020. Print 2021 Jan. Eur Respir J. 2021. PMID: 32703777 Free article.
Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries.
Schwœbel V, Trébucq A, Kashongwe Z, Bakayoko AS, Kuaban C, Noeske J, Harouna SH, Souleymane MB, Piubello A, Ciza F, Fikouma V, Gasana M, Ouedraogo M, Gninafon M, Van Deun A, Tagliani E, Cirillo DM, Koura KG, Rieder HL. Schwœbel V, et al. EClinicalMedicine. 2020 Feb 10;20:100268. doi: 10.1016/j.eclinm.2020.100268. eCollection 2020 Mar. EClinicalMedicine. 2020. PMID: 32300732 Free PMC article.
17 results